A Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Patients with Iron Deficiency Anemia in China
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
A Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Patients with Iron Deficiency Anemia in China ; volume:41 ; number:11 ; day:18 ; month:9 ; year:2024 ; pages:4191-4204 ; date:11.2024
Advances in therapy ; 41, Heft 11 (18.9.2024), 4191-4204, 11.2024
- Creator
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-024-02987-7
- URN
-
urn:nbn:de:101:1-2501022128182.757088447127
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:30 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Zhang, Fengkui
- Shen, Aizong
- Ahmed, Waqas
- Pollock, Richard
- SpringerLink (Online service)
Other Objects (12)
Cost-utility of ferric carboxymaltose (Ferinject®) for iron-deficiency anemia patients with chronic heart failure in South Korea
Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy
Cost-effectiveness of ferric citrate hydrate in patients with iron deficiency anemia
Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study
Individualized anemia management enhanced by ferric pyrophosphate citrate protocol
Safety, pharmacokinetics, and pharmacodynamics of intravenous ferric carboxymaltose in children with iron deficiency anemia
Correction to: Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study
Economic Evaluation of Ferric Carboxymaltose for the Management of Hemodialysis Patients with Iron Deficiency Anemia in Italy
Improved Hemoglobin Response with Ferric Carboxymaltose in Patients with Gastrointestinal-Related Iron-Deficiency Anemia Versus Oral Iron
High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment
Ferric pyrophosphate citrate: interactions with transferrin
Odd and Even Numbered Ferric Wheels
Cost-utility of ferric carboxymaltose (Ferinject®) for iron-deficiency anemia patients with chronic heart failure in South Korea
Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy
Cost-effectiveness of ferric citrate hydrate in patients with iron deficiency anemia
Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study
Individualized anemia management enhanced by ferric pyrophosphate citrate protocol
Safety, pharmacokinetics, and pharmacodynamics of intravenous ferric carboxymaltose in children with iron deficiency anemia
Correction to: Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study
Economic Evaluation of Ferric Carboxymaltose for the Management of Hemodialysis Patients with Iron Deficiency Anemia in Italy
Improved Hemoglobin Response with Ferric Carboxymaltose in Patients with Gastrointestinal-Related Iron-Deficiency Anemia Versus Oral Iron
High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment
Ferric pyrophosphate citrate: interactions with transferrin
Odd and Even Numbered Ferric Wheels
Cost-utility of ferric carboxymaltose (Ferinject®) for iron-deficiency anemia patients with chronic heart failure in South Korea
Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy
Cost-effectiveness of ferric citrate hydrate in patients with iron deficiency anemia
Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study
Individualized anemia management enhanced by ferric pyrophosphate citrate protocol
Safety, pharmacokinetics, and pharmacodynamics of intravenous ferric carboxymaltose in children with iron deficiency anemia
Correction to: Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study
Economic Evaluation of Ferric Carboxymaltose for the Management of Hemodialysis Patients with Iron Deficiency Anemia in Italy
Improved Hemoglobin Response with Ferric Carboxymaltose in Patients with Gastrointestinal-Related Iron-Deficiency Anemia Versus Oral Iron
High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment
Ferric pyrophosphate citrate: interactions with transferrin